Mucosal graft-vs-host disease.
Graft-vs-host disease (GVHD) is a serious complication of hematopoietic stem cell transplantation (HSCT). Indications for HSCT have greatly expanded, and more patients are undergoing HSCT today than ever before. In addition, the options for immunosuppressive therapy for both prevention and treatment of GVHD have also expanded. These changes have in turn altered the landscape of this disease. We have reviewed the current literature on this subject and presented an update on this disease with a particular emphasis on mucosal manifestations.
Lew
J
J
Laboratory of Immunology, National Eye Institute, Bethesda, MD, USA.
Smith
J A
JA
D003231:Conjunctivitis / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007765:Lacrimal Apparatus / Q000503:physiopathology; D009092:Mucous Membrane; D015423:Scleritis / Q000209:etiology; D013280:Stomatitis / Q000209:etiology; D014627:Vaginitis / Q000209:etiology; D014987:Xerostomia / Q000209:etiology